Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Umberto Vitolo

Showing results (181-190 of 212) with videos related to

Pageof 22
Sort By:
Blood|August 15, 2002
High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO)Marco Ladetto, Paolo Corradini, Sonia Vallet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2016
Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 StudyPier Luigi Zinzani, Alessandro Broccoli, Daniela Maria Gioia, et al.
Blood Advances|July 29, 2021
Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphomaJonathan C Strefford, Malgorzata Nowicka, Chantal E Hargreaves, et al.
Blood Advances|August 31, 2022
A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphomaCatherine Thieblemont, Loic Chartier, Ulrich Dührsen, et al.
Hemasphere|September 25, 2025
Bridging gaps in clinical trial accessibility and reimbursement for large B-cell lymphoma therapies across EuropeFlorence Broussais, Elise Pennings, Natacha Bolanos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2014
Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trialSara Galimberti, Stefano Luminari, Elena Ciabatti, et al.
Lancet (London, England)|May 30, 2026
Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trialGeorg Lenz, Marek Trněný, John M Burke, et al.
Blood Advances|January 5, 2024
IELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphomaAnnarita Conconi, Annalisa Chiappella, Andrés J M Ferreri, et al.
Leukemia & Lymphoma|April 5, 2018
Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana LinfomiFrancesco Zaja, Flavia Salvi, Maura Rossi, et al.
Hematological Oncology|May 29, 2023
Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment naïve advanced-stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana LinfomiMaria E Nizzoli, Martina Manni, Chiara Ghiggi, et al.
Pageof 22

Showing results (181-190 of 212) with videos related to

Sort By:
Pageof 22
Blood|August 15, 2002
High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO)Marco Ladetto, Paolo Corradini, Sonia Vallet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2016
Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 StudyPier Luigi Zinzani, Alessandro Broccoli, Daniela Maria Gioia, et al.
Blood Advances|July 29, 2021
Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphomaJonathan C Strefford, Malgorzata Nowicka, Chantal E Hargreaves, et al.
Blood Advances|August 31, 2022
A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphomaCatherine Thieblemont, Loic Chartier, Ulrich Dührsen, et al.
Hemasphere|September 25, 2025
Bridging gaps in clinical trial accessibility and reimbursement for large B-cell lymphoma therapies across EuropeFlorence Broussais, Elise Pennings, Natacha Bolanos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2014
Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trialSara Galimberti, Stefano Luminari, Elena Ciabatti, et al.
Lancet (London, England)|May 30, 2026
Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trialGeorg Lenz, Marek Trněný, John M Burke, et al.
Blood Advances|January 5, 2024
IELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphomaAnnarita Conconi, Annalisa Chiappella, Andrés J M Ferreri, et al.
Leukemia & Lymphoma|April 5, 2018
Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana LinfomiFrancesco Zaja, Flavia Salvi, Maura Rossi, et al.
Hematological Oncology|May 29, 2023
Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment naïve advanced-stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana LinfomiMaria E Nizzoli, Martina Manni, Chiara Ghiggi, et al.
Pageof 22